体外膜氧合治疗COVID-19相关重度ARDS的模拟目标试验分析
该研究基于4244例危重COVID-19成人患者的多中心队列,模拟目标试验比较IMV后7天内启动ECMO与不启动ECMO的策略。共1235例符合条件,其中164例启动ECMO。ECMO策略第7天生存概率较高(87% vs 83%),但第90天无差异(63% vs 65%);在高容量ECMO中心或特定ECMO网络区域、IMV后4天内启动及深度低氧患者中,ECMO与更高生存相关。
要点
- ECMO策略第7天生存率较高,但90天生存率与常规IMV无差异。
- 高容量ECMO中心或特定ECMO网络区域中,ECMO与更好结局相关。
- IMV后4天内启动ECMO及深度低氧患者中,ECMO与更高生存相关。
核心结论
- 在模拟目标试验中,ECMO与无ECMO策略的生存差异随时间变化,第7天ECMO组生存概率较高,第90天无差异。
- 在高容量ECMO中心或特定ECMO网络区域、IMV后4天内启动及深度低氧患者中,ECMO与更好结局相关。
研究设计与样本
- 多中心队列研究,纳入4244例危重COVID-19成人患者,模拟目标试验比较IMV后7天内启动ECMO与不启动ECMO的策略。
- 共1235例符合全部入选标准,其中164例启动ECMO;使用多变量Cox模型控制混杂。
主要发现
- ECMO策略第7天生存概率87% vs 83%,风险差4%(95%CI 0-9%)。
- 第90天生存概率63% vs 65%,风险差-2%(95%CI -10 to 5%)。
- 高容量ECMO中心或特定ECMO网络区域、IMV后4天内启动及深度低氧患者中,ECMO与更高生存相关。
关键数值与推荐
- 纳入标准:IMV后7天内,PaO2/FiO2 < 80或PaCO2 ⩾ 60 mm Hg。
- 共1235例符合全部入选标准,其中164例启动ECMO。
临床怎么用
- 在具备高容量ECMO中心或特定ECMO网络组织的区域,可考虑对符合条件的重度COVID-19 ARDS患者启动ECMO。
- 启动时机宜在IMV后4天内,并优先考虑深度低氧患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Whether patients with coronavirus disease (COVID-19) may benefit from extracorporeal membrane oxygenation (ECMO) compared with conventional invasive mechanical ventilation (IMV) remains unknown. Objectives: To estimate the effect of ECMO on 90-day mortality versus IMV only. Methods: Among 4,244 critically ill adult patients with COVID-19 included in a multicenter cohort study, we emulated a target trial comparing the treatment strategies of initiating ECMO versus no ECMO within 7 days of IMV in patients with severe acute respiratory distress syndrome (PaO2/FiO2 < 80 or PaCO2 ⩾ 60 mm Hg). We controlled for confounding using a multivariable Cox model on the basis of predefined variables. Measurements and Main Results: A total of 1,235 patients met the full eligibility criteria for the emulated trial, among whom 164 patients initiated ECMO. The ECMO strategy had a higher survival probability on Day 7 from the onset of eligibility criteria (87% vs. 83%; risk difference, 4%; 95% confidence interval, 0-9%), which decreased during follow-up (survival on Day 90: 63% vs. 65%; risk difference, -2%; 95% confidence interval, -10 to 5%). However, ECMO was associated with higher survival when performed in high-volume ECMO centers or in regions where a specific ECMO network organization was set up to handle high demand and when initiated within the first 4 days of IMV and in patients who are profoundly hypoxemic. Conclusions: In an emulated trial on the basis of a nationwide COVID-19 cohort, we found differential survival over time of an ECMO compared with a no-ECMO strategy. However, ECMO was consistently associated with better outcomes when performed in high-volume centers and regions with ECMO capacities specifically organized to handle high demand.
引用
- Hajage D, Combes A, Guervilly C, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome Associated with COVID-19: An Emulated Target Trial Analysis. Am J Respir Crit Care Med. 2022. PMID: 35533052. doi:10.1164/rccm.202111-2495OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。